22 Sep 2026
Disruptive Pharma divests GTX platform and retains rights to future royalty and milestone revenues
Disruptive Pharma AB (publ) ("Disruptive Pharma" or the "Company") today announced that it has entered into an agreement to sell the GTX platform to a wholly owned subsidiary of Aurelia Invest AB ("Aurelia"). The transaction is the result of the process initiated in June 2026 to evaluate strategic alternatives for the GTX platform, which was deemed to fall outside the business focus that Disruptive Pharma intends to pursue following the reverse takeover of Disruptive Pharma Holding AB.
Read More
18 Aug 2026
Disruptive Pharma to ring the opening bell at Nasdaq Stockholm
Disruptive Pharma AB (publ), formerly Guard Therapeutics International AB (publ), (“Disruptive Pharma” or the “Company”) will ring the opening bell at Nasdaq Stockholm on 21 August 2026. On the same day, the Company’s shares will begin trading under the new ticker symbol DPHA, replacing GUARD. The bell-ringing ceremony marks the completion of the reverse takeover of Disruptive Pharma Holding AB (publ) and the beginning of a new chapter for Disruptive Pharma as a listed company on Nasdaq First North Growth Market.
Read More
27 Jul 2026
· Regulatory information
Guard Therapeutics Completes Reverse Takeover of Disruptive Pharma and Executes In-Kind Share Issue
27 July 2026 – Guard Therapeutics International AB (publ) (to be renamed Disruptive Pharma AB (publ)) ("Guard Therapeutics" or the "Company") today announces that the reverse takeover (RTO) of Disruptive Pharma Holding AB (publ) ("Disruptive Pharma"), pursuant to the agreement entered into and announced on 10 June 2026, has been completed through the acquisition of 99.07 percent of the shares in Disruptive Pharma. The Company's Board of Directors has also today resolved on an In-kind issue of 24,420,434 shares as consideration for the shares acquired in Disruptive Pharma. As a result of the completion of the Transaction, the Company will change its name to Disruptive Pharma AB (publ) and a new Board of Directors and management team will assume office.
Read More
16 Jul 2026
· Regulatory information
Guard Therapeutics Receives Conditional Approval for Continued Listing on Nasdaq First North Growth Market and Publishes Company Description
Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") has today received conditional approval from Nasdaq Stockholm ("Nasdaq") for the continued listing of the Company's shares on Nasdaq First North Growth Market. The application for continued listing was submitted on 11 June 2026 as part of the implementation of the previously announced planned reverse takeover of Disruptive Pharma Holding AB (publ). The Company is also today publishing a company description.
Read More